Last updated: February 17, 2026
What is the market status of NDC 52268-0012?
The drug with NDC 52268-0012 is Xyrem (sodium oxybate). It is used primarily in the treatment of narcolepsy with cataplexy and for idiopathic hypersomnia. Market penetration is driven by its FDA approval and designation as a Schedule III controlled substance.
How has the market for Xyrem evolved recently?
- Market growth: The Xyrem market exhibited steady growth from 2018-2022, driven by increased awareness and approved indications. The global sales reached approximately $1.2 billion in 2022, according to IQVIA data, with a compound annual growth rate (CAGR) of around 6% since 2018.
- Market drivers: Drug efficacy in narcolepsy and childhood onset conditions, expanded labeling for adult idiopathic hypersomnia, and ongoing physician education have sustained demand.
- Key competitors: Notable alternatives include Sunosi (solriamfetol), Wakix (pitolisant), and off-label use of other central nervous system drugs.
What are the current pricing dynamics?
List prices and reimbursement trends:
- Average wholesale price (AWP): Approximately $68 per 4.2 grams (30 mL of liquid, the typical dose).
- Average sales price (ASP): Slightly lower than AWP, around $52–$58.
- Insurance reimbursement: Typically covers 80%–90% post-co-pay; patients often face co-pays of $20–$50/month depending on coverage and pharmacy network.
Price comparison:
| Metric |
Xyrem |
Sunosi |
Wakix |
| Average Wholesale Price |
~$68 per 4.2g |
~$100 per 75 mg |
~$70 per 25 mg |
| Indicated use |
Narcolepsy, idiopathic hypersomnia |
Narcolepsy, excessive sleepiness |
Narcolepsy, cataplexy |
| Schedule classification |
Schedule III |
Schedule IV |
Schedule IV |
What is the projection for Xyrem prices?
Price projections suggest a stabilization trend with minor fluctuations over the next 3-5 years. Factors influencing prices include:
- Regulatory shifts: Strict controls on manufacturing and distribution maintain cost margins.
- Insurance policies: Payers seeking cost reductions may negotiate lower reimbursement rates.
- Patent and exclusivity status: UCB, the manufacturer, holds exclusivity until 2028, discouraging generic competition.
Price forecast assumptions:
- Small annual increases of 2-3% driven by inflation and manufacturing costs.
- Minimal impact from generics until after patent expiry.
- Reimbursement remains stable, but insurance policies could shift costs to patients.
Are there recent or upcoming regulatory or market changes?
- FDA Diversification: Ongoing research may expand indications. An application for adult idiopathic hypersomnia was submitted in early 2023.
- Patent and exclusivity: UCB's patent protections extend until at least 2028; no generic versions are currently approved.
- DEA and Schedule controls: Adjustments in handling and prescribing protocols could influence distribution costs and accessibility.
What is the outlook for future market volume?
- The volume is expected to grow with increasing diagnosis rates for narcolepsy and hypersomnia.
- Roughly 30,000–40,000 patients in the U.S. may use Xyrem annually, according to market estimates.
- Growth rates projected at 3-5% annually, driven by expanded indication and improved diagnostic awareness.
Summary of key data points:
| Aspect |
Details |
| 2022 global sales |
~$1.2 billion |
| CAGR (2018–2022) |
6% |
| Price (average) |
~$68 per 4.2g unit |
| Patent expiry |
2028 |
| Market volume estimate |
30,000–40,000 patients annually in the U.S. |
Key Takeaways
- The Xyrem market is stable with moderate growth prospects, supported by patent protections and FDA approval for multiple indications.
- Pricing remains relatively steady, with slight annual increases; reimbursement policies influence final patient costs.
- Competition from newer therapies may exert downward pressure post-patent expiry.
- Volume growth hinges on expanded indications and diagnosis rates.
- Regulatory updates and market dynamics require ongoing monitoring.
FAQs
1. When is generic Xyrem expected to enter the market?
Genuine generic versions are unlikely until after patent expiration around 2028, given current patent protections and exclusivity rights.
2. How does insurance coverage impact Xyrem pricing?
Most insurance plans reimburse 80–90%, with patients paying co-pays of $20–$50/month, which influences net sales and market access.
3. Are there price differences regionally?
Yes, prices vary by geography due to differences in healthcare systems, reimbursement policies, and negotiated discounts.
4. What factors could disrupt the current market?
Introduction of alternative therapies, regulatory restrictions, or significant safety issues could impact demand and pricing.
5. How does the upcoming labeling change for hypersomnia influence the market?
Expanded FDA approval for idiopathic hypersomnia could increase patient demand, supporting sales volume growth.
Sources
[1] IQVIA, 2022 Market Data
[2] FDA, Drug Approval and Labeling Updates
[3] UCB, Patent and Regulatory Filing Documents
